new version of the media release de und en
Dear all,
please see attached new draft versions of the PR for Thursday. I would need final comments till Monday evening, if possible.
thanks to te good suggestions from Katherine and Daniela (FOE Germany) I found a way to shorten it and two include two quotes.
After having read the proposals made by Katherine, I think it is important to not have to many details in the PR. We might draft a letter to the EPO where we can include further details, but anyway they are in the report.
So I used mostly used the the more simplified version of Daniela. Hope everybody can agree. You also can use the draft for preparing your own PR, but I guess most of yow will wait for the Enlarged Board of Appeal.
Short notice: I again asked the EPO and they again responded that they do not know the date. But we will get informed (we still have to prepare a PR in two versions for that day).
I will approach the German media agency (dpa) if they are interested to get the report before hand.
Cheers
Christoph
dear all,
Here are my comments which I did yesterday, so it's on the previous version, but I've quickly made a few similar comments in the new version. Both are attached. It's only to shift in nuance here and there, an attempt to avoid potential confusion (regarding our campaign to keep new GM regulated; and industry's attempt to equate random mutagenesis and genome editing). Just see if it works.
my two cents,
Nina
Op 19/04/20 om 10:11 schreef Christoph Then:
Dear all,
please see attached new draft versions of the PR for Thursday. I would need final comments till Monday evening, if possible.
thanks to te good suggestions from Katherine and Daniela (FOE Germany) I found a way to shorten it and two include two quotes.
After having read the proposals made by Katherine, I think it is important to not have to many details in the PR. We might draft a letter to the EPO where we can include further details, but anyway they are in the report.
So I used mostly used the the more simplified version of Daniela. Hope everybody can agree. You also can use the draft for preparing your own PR, but I guess most of yow will wait for the Enlarged Board of Appeal.
Short notice: I again asked the EPO and they again responded that they do not know the date. But we will get informed (we still have to prepare a PR in two versions for that day).
I will approach the German media agency (dpa) if they are interested to get the report before hand.
Cheers
Christoph
Npos_2018 mailing list Npos_2018@testbiotech.de https://lists.testbiotech.de/cgi-bin/mailman/listinfo/npos_2018
Dear Nina, dear all
I do not think that we should argue that we are against all patents on seeds – the common denominator of NPOS and our main goal was always to combat patents on conventionally bred plants, native traits, etc.
It would need a broader discussion if we like to campaign against patents on GMOs. Therefore I would not mention this in the pressrelease.
Best
François
Von: Npos_2018 npos_2018-bounces@testbiotech.de Im Auftrag von Nina Holland Gesendet: Sonntag, 19. April 2020 15:48 An: npos_2018@testbiotech.de Betreff: Re: [Npos_2018] new version of the media release de und en
dear all,
Here are my comments which I did yesterday, so it's on the previous version, but I've quickly made a few similar comments in the new version. Both are attached. It's only to shift in nuance here and there, an attempt to avoid potential confusion (regarding our campaign to keep new GM regulated; and industry's attempt to equate random mutagenesis and genome editing). Just see if it works.
my two cents,
Nina
Op 19/04/20 om 10:11 schreef Christoph Then:
Dear all,
please see attached new draft versions of the PR for Thursday. I would need final comments till Monday evening, if possible.
thanks to te good suggestions from Katherine and Daniela (FOE Germany) I found a way to shorten it and two include two quotes.
After having read the proposals made by Katherine, I think it is important to not have to many details in the PR. We might draft a letter to the EPO where we can include further details, but anyway they are in the report.
So I used mostly used the the more simplified version of Daniela. Hope everybody can agree. You also can use the draft for preparing your own PR, but I guess most of yow will wait for the Enlarged Board of Appeal.
Short notice: I again asked the EPO and they again responded that they do not know the date. But we will get informed (we still have to prepare a PR in two versions for that day).
I will approach the German media agency (dpa) if they are interested to get the report before hand.
Cheers
Christoph
_______________________________________________ Npos_2018 mailing list Npos_2018@testbiotech.de mailto:Npos_2018@testbiotech.de https://lists.testbiotech.de/cgi-bin/mailman/listinfo/npos_2018
Dear Nina
thanks for your comments!
as Francois explained, we would need more discussions before including such a statement.
further it make no sense, to say "The examples in this report are derived from conventional breeding methods *or* on random processes, and crossing and selection."
conventional breeding *is* nothing else than using random processes and crossing or selection.
Finally, the EU Directive does not really limit the patentability of plants, it is only adding to the interpretation of the EPC. The Enlarged Board of Appeal now asks, if the interpretation of the EU (rule 28 (2)) is in line with the EPC. If not, the EU has nothing to say.
I will now shortly check my lasts drafts and then then resend it and also send off for final English editing.
Before that, I also saw some comments from FOE Germany, I will try to check.
Cheers
Christoph
Am 19.04.20 um 15:47 schrieb Nina Holland:
dear all,
Here are my comments which I did yesterday, so it's on the previous version, but I've quickly made a few similar comments in the new version. Both are attached. It's only to shift in nuance here and there, an attempt to avoid potential confusion (regarding our campaign to keep new GM regulated; and industry's attempt to equate random mutagenesis and genome editing). Just see if it works.
my two cents,
Nina
Op 19/04/20 om 10:11 schreef Christoph Then:
Dear all,
please see attached new draft versions of the PR for Thursday. I would need final comments till Monday evening, if possible.
thanks to te good suggestions from Katherine and Daniela (FOE Germany) I found a way to shorten it and two include two quotes.
After having read the proposals made by Katherine, I think it is important to not have to many details in the PR. We might draft a letter to the EPO where we can include further details, but anyway they are in the report.
So I used mostly used the the more simplified version of Daniela. Hope everybody can agree. You also can use the draft for preparing your own PR, but I guess most of yow will wait for the Enlarged Board of Appeal.
Short notice: I again asked the EPO and they again responded that they do not know the date. But we will get informed (we still have to prepare a PR in two versions for that day).
I will approach the German media agency (dpa) if they are interested to get the report before hand.
Cheers
Christoph
Npos_2018 mailing list Npos_2018@testbiotech.de https://lists.testbiotech.de/cgi-bin/mailman/listinfo/npos_2018
-- -- *Nina Holland Corporate Europe Observatory (CEO)* Phone: +32 (0)289 309 30 Twitter: @nina_holland www.corporateeurope.org
Npos_2018 mailing list Npos_2018@testbiotech.de https://lists.testbiotech.de/cgi-bin/mailman/listinfo/npos_2018
participants (3)
-
Christoph Then -
francois.meienberg＠prospecierara.ch -
Nina Holland